Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial

INTRODUCTION: Radiation-induced cognitive decline (RICD) is a late effect of radiotherapy (RT) occurring in 30–50% of irradiated brain tumor survivors. In preclinical models, pioglitazone prevents RICD but there are little safety data on its use in non-diabetic patients. We conducted a dose-escalati...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Cancer Res Clin Oncol
Päätekijät: Cramer, Christina K., Alphonse-Sullivan, Natalie, Isom, Scott, Metheny-Barlow, Linda J., Cummings, Tiffany L., Page, Brandi R., Brown, Doris R., Blackstock, Arthur W., Peiffer, Ann M., Strowd, Roy E., Rapp, Stephen, Lesser, Glenn J., Shaw, Edward G., Chan, Michael D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6805132/
https://ncbi.nlm.nih.gov/pubmed/30417218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-018-2791-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia